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Abstract
Background: Many of the mutations accumulated by naturally evolving proteins are neutral in the sense that
they do not significantly alter a protein’s ability to perform its primary biological function. However, new protein
functions evolve when selection begins to favor other, “promiscuous” functions that are incidental to a protein’s
biological role. If mutations that are neutral with respect to a protein’s primary biological function cause substantial
changes in promiscuous functions, these mutations could enable future functional evolution.
Results: Here we investigate this possibility experimentally by examining how cytochrome P450 enzymes that
have evolved neutrally with respect to activity on a single substrate have changed in their abilities to catalyze
reactions on five other substrates. We find that the enzymes have sometimes changed as much as four-fold in the
promiscuous activities. The changes in promiscuous activities tend to increase with the number of mutations, and
can be largely rationalized in terms of the chemical structures of the substrates. The activities on chemically similar
substrates tend to change in a coordinated fashion, potentially providing a route for systematically predicting the
change in one function based on the measurement of several others.
Conclusions: Our work suggests that initially neutral genetic drift can lead to substantial changes in protein
functions that are not currently under selection, in effect poising the proteins to more readily undergo functional
evolution should selection “ask new questions” in the future.
Background
Nature employs proteins for a vast range of tasks,
and their capacity to evolve to perform diverse func-
tions is one of the marvels of biology. Recently, it
has become possible to reconstruct convincing sce-
narios for how new protein functions evolve. One
of the most important conclusions of this work is
that the initial steps may occur even before the
new functions come under selection [1–6]. The rea-
son is that in addition to their primary biological
functions, most proteins are at least modestly effec-
tive at performing a range of other “promiscuous”
functions [1, 2, 7–10]. In laboratory experiments,
selection can rapidly increase these promiscuous
functions, often without much immediate cost to
a protein’s original function [2]. In a particularly
compelling set of experiments, Tawfik and coworkers
have shown that selection for promiscuous activity
likely explains the origin and evolution of a bacterial
enzyme that hydrolyzes a synthetic compound only
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recently introduced into the environment [2, 11, 12].
Mounting evidence therefore supports the idea that
new protein functions evolve when selection favors
mutations that increase an existing weak promiscu-
ous function.
But for as long as 50 years, since Linus Pauling
and Emile Zuckerkandl published their seminal anal-
ysis of molecular change in proteins [13], it has been
clear that just a small fraction of the mutations that
accumulate in naturally evolving proteins are driven
by selection for a new function. Instead, most of the
mutations responsible for natural sequence diver-
gence do not change a protein’s primary biological
function, but rather are due to either neutral ge-
netic drift [14] or pressure for a subtle recalibration
of protein properties unrelated to the acquisition of
an entirely new function [15]. However, even though
most mutations accumulate under the constraint
that they not interfere with a protein’s primary
function, they could still substantially alter other,
promiscuous functions. Such alterations could then
aid in the subsequent evolution of new functions.
Here we have experimentally investigated this
possibility using a set of enzymes that have under-
gone genetic drift that is neutral with respect to a
well-defined laboratory selection criterion for enzy-
matic activity on a single substrate [16]. We have
examined how these enzymes have changed in their
promiscuous activities on five other substrates. As
described below, we find that the enzymes have often
undergone substantial changes in their promiscuous
activities, suggesting that neutral genetic drift could
play an important role in enabling future functional
evolution.
Results and Discussion
A set of neutrally evolved cytochrome P450 en-
zymes
We focused our analysis on cytochrome P450 pro-
teins. P450s are excellent examples of enzymes that
can evolve to catalyze new reactions, since they are
involved in a wide range of important functions such
as drug metabolism and steroid biosynthesis [17,18].
We worked with P450 BM3, a cytosolic bacterial
enzyme that catalyzes the subterminal hydroxyla-
tion of medium- and long-chain fatty acids [19].
We have previously described a set of P450 BM3
heme domain variants that were created by lab-
oratory neutral evolution from a common parent
sequence [16]. Here we briefly recap the procedure
used to create these P450s in order to explain their
origin and why they can properly be viewed as the
product of neutral genetic drift.
The essential difference between neutral genetic
drift and adaptive evolution is that in the former
case mutations that have no substantial effect on
fitness spread stochastically in a population, while
in the latter case mutations spread because they are
beneficial and so favored by selection. Of course, it
may be difficult to discern whether a specific muta-
tion in a natural population has spread neutrally or
due to favorable selection. But in the laboratory it
is possible to define an arbitrary selection criterion
to ensure that all mutations spread due to neutral
genetic drift. Specifically, we imposed the require-
ment that the P450s had to hydroxylate the sub-
strate 12-p-nitrophenoxydodecanoic acid (12-pNCA)
with an activity exceeding a specific threshold [16].
All mutant P450s were therefore straightforwardly
classified as either functional (if they exceeded the
threshold) or nonfunctional (if they did not). While
this selection criterion is obviously a simplification
of natural evolution, we believe that for the cur-
rent purpose it is a reasonable abstraction of the
evolutionary requirement that an enzyme’s primary
activity exceed some critical level in order to allow
its host organism to robustly survive and reproduce.
To implement laboratory neutral evolution using
this selection criterion, we began with a single par-
ent P450 BM3 heme domain variant (called R1-11)
and used error-prone PCR to create randommutants
of this parent [16]. Mutants that failed to yield suf-
ficient active protein to hydroxylate at least 75% of
the 12-pNCA of the R1-11 parent when expressed in
Escherichia coli were immediately eliminated, while
all other mutants were carried over to the next gen-
eration with equal probability. Any mutations that
spread among the offspring sequences were there-
fore by definition due to neutral genetic drift, since
there was no opportunity for any functional mutant
to be favored over any other. We emphasize that
the fact that the mutations spread due to neutral
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genetic drift does not mean that they have no ef-
fect on the protein’s properties. Indeed, one of the
growing realizations about protein evolution is that
mutations that spread by neutral genetic drift may
still have an impact on future evolution [20,21]. One
mechanism for this impact is that neutral genetic
drift can change a protein’s stability and so alter
its tolerance to future mutations [22–24]. As will
be demonstrated below, another mechanism is that
neutral genetic drift can alter a protein’s promiscu-
ous functions.
As described previously [16], the end result of
the neutral evolution was 44 different P450 vari-
ants, each of which satisfied the selection criterion
for activity on 12-pNCA (these are the combined
final sequences from the monomorphic and poly-
morphic populations in [16]). For the current study,
we analyzed the promiscuous activities of 34 of these
neutrally evolved P450 variants. The sequence di-
versity of these P450s is shown in the phylogenetic
tree of Figure 1; they have accumulated an average
of four nonsynonymous mutations each.
Activities of the neutrally evolved P450 enzymes
All of the P450 variants had evolved under selection
solely for their ability to hydroxylate 12-pNCA. We
examined their promiscuous hydroxylation activities
on the five other substrates shown at the top of Fig-
ure 2. Two of these promiscuous substrates, propra-
nolol and 2-amino-5-chlorobenzoxazole (also known
as zoxazolamine), are drugs that are metabolized
by human P450s [25, 26]. The other three promis-
cuous substrates, 11-phenoxyundecanoic acid, 2-
phenoxyethanol, and 1,2-methylenedioxybenzene,
are organic compounds of increasing structural dis-
similarity to 12-pNCA. The parent P450 possessed
at least some hydroxylation activity on all of these
substrates (throughout the remainder of this work,
“activity” refers to total substrate turnovers per en-
zyme).
We measured the activities of all 34 neutrally
evolved P450s on the five promiscuous substrates as
well as 12-pNCA. Figure 2 shows the fold change in
activity of each of the variants relative to the par-
ent P450 on all six substrates, and Figure 3 shows
the same data with standard errors. As is apparent
from these figures, many of the neutrally evolved
P450s have undergone changes in their activities
that substantially exceeded the standard errors of
the measurements. Even on 12-pNCA, some of the
variants have undergone modest increases or very
mild decreases in activity . The modest increases in
12-pNCA activity were unsurprising, since the par-
ent P450 only hydroxylates 12-pNCA with about
a quarter of the activity reported for a P450 engi-
neered for maximal 12-pNCA activity [27]. Likewise,
the mild decreases in 12-pNCA activity were due to
the fact that during neutral evolution the P450s
were only required to maintain this activity above a
minimal threshold (75% of the total 12-pNCA con-
version of the parent protein when expressed in E.
coli [16]). The changes in the promiscuous activities
were often much larger than those on 12-pNCA. For
example, several of the neutrally evolved variants
have undergone nearly four-fold increases in activity
on one or more of 2-phenoxyethanol, 2-amino-5-
chlorobenzoxazole, and 1,2-methylenedioxybenzene.
Other variants have experienced equally large de-
creases in one or more of the promiscuous activities.
Broad patterns of change in activity can be ratio-
nalized in terms of substrate properties
The data in Figures 2 and 3 clearly indicate that
some of the P450s have undergone substantial
changes in their activities. In an effort to under-
stand the nature of these changes, we sought to
determine whether there were any clear patterns
in the activities. In Figure 2, the substrates have
been hierarchically clustered so that each succes-
sive cluster contains substrates on which the P450s
have increasingly similar activities (the clustering is
illustrated by the tree-like dendrogram at the top
of the figure, with similar substrates in adjacent
columns). The clustering of the substrates is readily
rationalized in terms of their chemical structures.
For example, 2-amino-5-chlorobenzoxazole and 1,2-
methylenedioxybenzene cluster, meaning that P450s
with high activity on one of these substrates also
tend to have high activity on the other. Presumably,
they cluster because the similarity of their structures
(both are fusions of six and five membered rings)
means that they have similar modes of docking in the
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substrate binding pocket. Likewise, 12-pNCA and
11-phenoxyundecanoic acid are phenoxycarboxylic
acids of similar chain length, and are in the same
cluster. To a lesser extent, 2-phenoxyethanol resem-
bles 12-pNCA and 11-phenoxyundecanoic acid in its
phenolic ether structure, and it falls into a higher
level cluster with these two substrates. Propra-
nolol shares a fused ring structure with 2-amino-5-
chlorobenzoxazole and 1,2-methylenedioxybenzene,
and these three substrates share a common higher
level cluster. Overall, the hierarchical clustering in-
dicates that substrates that appear similar to the
human eye are also “seen” this way by the P450s,
since the P450s tend to increase or decrease their
activities on these substrates in a coordinated fash-
ion.
Figure 2 also shows the P450 variants arranged
in hierarchical clusters. A visual inspection imme-
diately indicates that there is an overall association
among all of the activities. Some of the P450 vari-
ants (redder rows) tend to show improved activity
on most substrates, while others (bluer rows) tend to
show decreased activity on most substrates. Taken
together with the clustering of the similar substrates,
this overall association suggests that there are two
main trends in the activity changes. First, the P450s
appear to have undergone general changes in their
catalytic abilities that are manifested by broad in-
creases or decreases in activity on all substrates.
Second, the P450s appear to have experienced shifts
in specificity to favor either the fused ring or the
phenolic ether substrates.
To test whether these two apparent trends in
activity changes are supported by a quantitative
examination of the data, we performed principal
component analysis. Principal component analy-
sis is a well-established mathematical technique for
finding the dominant components of variation in a
data set, essentially by diagonalizing the covariance
matrix. As suggested by the foregoing visual inspec-
tion, principal component analysis revealed that two
components explained most of the changes in P450
activity (Table 1). The first component contained
positive contributions from all six substrates, and so
represents a general improvement in catalytic ability.
The second component contained positive contribu-
tions from the fused ring substrates and negative
contributions from the phenolic ether substrates,
and so represents an increased preference for the
former class of substrates over the latter. Together,
these two components explain 82% of the variance
in activities among the 34 P450 variants. The re-
maining 18% of the variance is explained by the four
remaining components, which represent more subtle
shifts in activity that are less easily rationalized with
intuitive chemical arguments.
Overall distributions of change in the activities
The preceding sections have demonstrated that neu-
tral genetic drift can lead to substantial changes in
P450 activities, and that many of these changes can
be understood as resulting from either fairly general
increases/decreases in catalytic ability or shifts in
preference for different broad classes of substrate
structures. In this section, we examine whether
there are any pervasive trends in the distributions
of activity changes — for example, did most of the
promiscuous activities tend to increase or decrease?
If a property is not under any evolutionary con-
straint, then during neutral genetic drift its values
might be expected to be distributed in a roughly
Gaussian fashion, as the neutrally evolving proteins
freely sample from the presumably normal underly-
ing distribution. On the other hand, if a property is
constrained by selection to remain above a certain
threshold, then during neutral genetic drift its val-
ues should display a truncated distribution since se-
lection culls proteins with values that fall below the
threshold (such a distribution has been predicted for
protein stability by simulations [28] and theory [21]).
Figure 4 shows the distribution of changes in ac-
tivity for each of the six substrates. The distribution
for 12-pNCA appears to be truncated on the left,
as expected since the P450s neutrally evolved under
a requirement to maintain the ability to hydroxy-
late 12-pNCA. Some of the P450s have undergone
a mild decrease in 12-pNCA activity, reflective of
the fact that the neutral evolution selection crite-
rion provided a small amount of latitude by allow-
ing the total amount of hydroxylated 12-pNCA to
drop to 75% of the parental value [16]. A number
of P450s have neutrally evolved 12-pNCA activity
that modestly exceeds that of the parent — again
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unsurprising, because the parental 12-pNCA activ-
ity falls well below the maximal value achievable
for this type of protein [27]. The distribution for
11-phenoxyundecanoic acid resembles that for 12-
pNCA, probably because activities on these two
chemically similar substrates are highly linked, as
discussed in the previous section.
The other four promiscuous activities are less
linked to 12-pNCA activity, and their distribu-
tions are much more symmetric. The symmetric
shapes of these distributions suggest that neu-
tral genetic drift has sampled from a roughly
Gaussian distribution for these four promiscu-
ous activities. For three of the substrates (pro-
pranolol, 2-amino-5-chlorobenzoxazole, and 1,2-
methylenedioxybenzene), the distributions of activi-
ties are approximately centered around the parental
activity. This centering indicates that the promis-
cuous activities of the parent on these three sub-
strates are typical of what would be expected of
a neutrally evolved P450. The distribution for 2-
phenoxyethanol, on the other hand, is shifted to-
wards activities higher than that of the parent. This
shift indicates that the parent is less active on 2-
phenoxyethanol than a typical neutrally evolved
P450.
If the activity distributions of Figure 4 truly
reflect what would be expected after a very long
period of neutral genetic drift (i.e., if they are “equi-
librium” distributions), then each variant represents
a random sample from the underlying distribution
of activities among all P450s that can neutrally
evolve under this selection criterion. In this case,
there should be no correlation between the extent
of change in activity and the number of accumu-
lated mutations, since the P450s should have lost
all “memory” of the parent’s activity. On the other
hand, if there has not been enough neutral genetic
drift to completely eliminate residual memory of the
parent’s activity, then variants with fewer mutations
should more closely resemble the parent’s activity
profile. To test whether the activity distributions of
the P450 variants had equilibrated, we computed the
correlation between the magnitude of each variant’s
change in activity and the number of nonsynony-
mous mutations it possessed relative to the parent.
Table 2 shows that the magnitude of activity change
is positively correlated with the number of mutations
for all six substrates. Although the correlations for
the individual substrates are mostly not statistically
significant due to the small number of samples, the
overall correlation for all six substrates is highly sig-
nificant (P = 10−3). Therefore, the P450 activities
are still in the process of diverging from the parental
values by neutral genetic drift. If the variants were
to undergo further neutral genetic drift, we would
expect to see even larger changes in their promiscu-
ous activities.
We also examined whether P450 variants with
mutations near the substrate binding pocket were
more likely to have undergone large changes in their
activities. Five of the P450 variants had a mutation
to a residue that was within 5 A˚ of the surrogate
substrate in the P450 BM3 crystal structure [29]:
variant M2 had A74V, M8 had A330V, M13 had
M354I, M15 had A74P, and M24 had I263V [16].
Two of these mutated residues are of clear impor-
tance, since mutating residue 74 has previously been
shown to shift substrate specificity [25, 30, 31] and
residue 263 plays a role in the substrate-induced
conformational shift [32]. We compared the activity
changes for the five variants with mutations near
the binding pocket to those for the 29 variants with-
out any such mutations, computing the magnitude
of activity change as the absolute value of the log-
arithm (base two) of the fold change in activity
averaged over all six substrates. The average mag-
nitude of activity change for the five variants with
mutations near the active site was 0.88, while the
average for the other 29 variants was 0.47. These
averages are significantly different, with an unequal
variance T-test P -value of 10−2. Therefore, variants
with mutations near the substrate binding pocket
are especially likely to have altered activities, al-
though many variants without mutations near the
pocket also underwent substantial activity changes.
Conclusions
We have shown that neutral genetic drift can lead
to changes of as much as four-fold in the promis-
cuous activities of P450 proteins. The ubiquity
of these changes is striking — even though many
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of the neutrally evolved P450s had only a hand-
ful of mutations, most of them had experienced
at least some change in their promiscuous activi-
ties. P450s may be especially prone to this type
of change, since their catalytic mechanism involves
large substrate-induced conformational shifts [33]
that can be modulated by mutations distant from
the active site [30,34,35]. In addition, P450s have a
tendency to eventually undergo irreversible inactiva-
tion that can be promoted by reduced coupling be-
tween substrate binding and conformational shifts,
as well as by other poorly understood determinants
of catalytic stability [19, 36, 37]. There are therefore
ample opportunities for mutations that spread by
neutral genetic drift to cause subtle alterations in a
P450’s promiscuous activities. But we believe that
neutral genetic drift is also likely to cause substan-
tial changes in the promiscuous activities of enzymes
with other catalytic mechanisms. In support of this
idea, a recent study by Tawfik and coworkers [38]
indicates that mutations with little effect on the
native lactonase activity of serum paraoxonase can
alter this enzyme’s promiscuous activities. Taken
together, this study and our work suggest that neu-
tral genetic drift allows for changes in promiscuous
protein functions. These changes could in turn have
important implications for future functional evolu-
tion. For example, one can easily imagine a scenario
in which neutral genetic drift enhances a promis-
cuous protein function, and then a subsequent gene
duplication allows natural selection to transform one
of the genes into the template for a protein with a
full-fledged new functional role [1–6].
One of the most attractive aspects of our study
is the degree to which the changes in P450 activities
during neutral genetic drift could be understood in
terms of the chemical structures of the substrates.
Neutral genetic drift did not simply cause unpre-
dictable shifts in activities. Instead, most of the
variation was explained by two eminently intuitive
components: an overall increase or decrease in cat-
alytic ability, and a preference for either fused ring
or phenolic ether substrates. We have suggested that
neutral genetic drift under a fixed selection criterion
can be viewed as sampling underlying “equilibrium”
distributions of activities. The distributions for dif-
ferent activities are linked, since we have shown that
P450s with good activity on one substrate will fre-
quently also be highly active on chemically similar
substrates (similar linkages have been observed in
P450s created by recombination [39]). So while it
may be impossible to know exactly how any specific
mutation will affect a given activity, measuring a
handful of activities allows one to make relatively
accurate predictions about other closely linked activ-
ities. The prerequisite for making such predictions
is an understanding of the linkages among activities
in the set of sequences explored by neutral genetic
drift (the neutral network). We have made the
first steps in elucidating these linkages for P450s
that have neutrally evolved under one specific selec-
tion regime. The linkages are very similar to those
that would have been made by an organic chemist
grouping the substrates on the basis of their chem-
ical structures. Knowledge of these linkages is of
use in understanding the origins of enzyme speci-
ficity [10, 40] — if an enzyme displays high activity
on one substrate but low activity on another, then
either these two activities are negatively linked dur-
ing neutral genetic drift or selection has explicitly
disfavored one of them.
Our work also has implications for the general
relationship between neutral genetic drift and adap-
tive evolution. A number of studies focused on
RNA [41–43] or computational systems [44,45] have
suggested that genetic drift might aid in adaptive
evolution. Our study and that of Tawfik and cowork-
ers [38] support this notion for the evolution of new
protein functions. However, the way that drift in
promiscuous functions promotes adaptive evolution
is slightly different than the paradigm proposed for
RNA [41–43] and computational systems [44,45]. In
those systems, neutral genetic drift is envisioned as
allowing a sequence to move along its neutral net-
work until it reaches a position where it can jump
to a new higher-fitness and non-overlapping neutral
network. In contrast, promiscuous protein functions
change even as a protein drifts along a single neu-
tral network. The adaptive benefits of this drift
come when new selective pressures suddenly favor a
previously irrelevant promiscuous function, in effect
creating a new neutral network that overlaps with
parts of the old one.
Overall, experiments have now demonstrated
two clear mechanisms by which neutral genetic drift
can aid in the evolution of protein functions. In the
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first mechanism, neutral genetic drift fixes a muta-
tion that increases a protein’s stability [20, 21, 46],
thereby improving the protein’s tolerance for subse-
quent mutations [22–24], some of which may confer
new or improved functions [24]. In the second mech-
anism, which was the focus of this work and the
recent study by Tawfik and coworkers [38], neu-
tral genetic drift enhances a promiscuous protein
function. This enhancement poises the protein to
undergo adaptive evolution should a change in se-
lection pressures make the promiscuous function
beneficial at some point in the future.
Methods
Determination of P450 activities
We attempted to determine the activities of all 44
neutrally evolved P450 variants described in [16]
(22 from the final monomorphic populations and
22 from the final polymorphic population). Ten
of these variants expressed relatively poorly in the
procedure used here (as described in more detail
below), and so were eliminated from further anal-
ysis since their low expression led to large errors
in the activity measurements. That left activity
data for the 34 neutrally evolved P450 variants
listed in Figures 2 and 3, as well as for the R1-
11 neutral evolution parent. The activities for
each of these P450 variants were measured on all
six substrates (12-pNCA, 2-phenoxyethanol, pro-
pranolol, 11-phenoxyundecanoic acid, 2-amino-5-
chlorobenzoxazole, and 1,2-methylenedioxybenzene).
In all cases, the activities represent the total amount
of product produced after two hours, and so are in
units of total turnovers per enzyme. P450 BM3
enzymes typically catalyze only a finite number of
reaction cycles before becoming irreversibly inacti-
vated, and we believe that all reactions were essen-
tially complete after two hours, so these activities
should represent the total turnovers of the enzymes
during their catalytic lifetimes.
To obtain P450 protein for the activity measure-
ments, we expressed the protein using catalase-free
Escherichia coli [47] containing the encoding gene on
the isopropyl β-D-thiogalactoside (IPTG) inducible
pCWori [47] plasmid (the catalase is removed since
it breaks down the hydrogen peroxide used by the
P450). The sequences of the P450 variants are de-
tailed in [16]. We used freshly streaked cells to
inoculate 2 ml cultures of Luria Broth (LB) supple-
mented with 100 µg/ml of ampicillin, and grew these
starter cultures overnight with shaking at 37oC. We
then used 0.5 ml from these starter cultures to in-
oculate 1 L flasks containing 200 ml of terrific broth
(TB) supplemented with 100 µg/ml of ampicillin.
The TB cultures were grown at 30oC and 210 rpm
until they reached an optical density at 600 nm of
≈0.9, at which point IPTG and δ-aminolevulinic
acid were added to a final concentration of 0.5 mM
each. The cultures were grown for an additional 19
hours, then the cells were harvested by pelletting 50
ml aliquots at 5,500 g and 4oC for 10 min, and stored
at -20oC. To obtain clarified lysate, each pellet was
resuspended in 8 ml of 100 mM [4-(2-hydroxyethyl)-
1-piperazinepropanesulfonic acid] (EPPS), pH 8.2
and lysed by sonication, while being kept on ice.
The cell debris was pelleted by centrifugation at
8,000 g and 4oC for 10 minutes, and the clarified
lysate was decanted and kept on ice.
To perform the assays, various dilutions of the
clarified lysate were used to construct a standard
curve. For each sample, we prepared dilutions of the
clarified lysate in the 100 mM EPPS (pH 8.2) buffer
to create samples for the standard curves. The di-
lutions were 100% clarified lysate (undiluted), 67%
lysate, 40% lysate, 25% lysate, 17% lysate, 10%
lysate, 6.7% lysate, and 4.0% lysate. Similar dilu-
tions were also prepared of the clarified lysate of E.
coli cells carrying a null pCWori plasmid in order to
assess the background readings from lysate without
any P450. A pipetting robot was then used to dis-
pense 80 µl of this series of clarified lysate dilutions
into 96-well microtiter plates. Duplicate microtiter
plates were then assayed for P450 concentration
and total enzymatic activity on each of the six sub-
strates. The R1-11 parent was assayed four times
rather than in duplicate. To minimize variation, all
of these assays were performed in parallel, with the
same stock solutions, and on the same day.
The P450 concentration was determined using
the carbon monoxide (CO) difference spectrum as-
say [48]. Immediately before use, we prepared a
5× stock solution of 50 mM sodium hydrosulfite
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in 1.3 M potassium phosphate, pH 8.0. A multi-
channel pipette was used to add 20 µl of this stock
solution to each well of the microtiter plates (which
contained 80 µl of a dilution of clarified lysate),
so that the final sodium hydrosulfite concentration
was 10 mM in each well. The plates were briefly
mixed and the absorbances were read at 450 and
490 nm. The plates were then incubated in a CO
binding oven [48] for 10 minutes to bind CO to the
iron. The absorbance was then again read at 450
and 490 nm. The amount of P450 is proportional to
the increase in the magnitude of the absorbance at
450 nm minus the absorbance at 490 nm. At each
dilution along the standard curve, the reading for
the null control (lysate dilutions without P450) was
subtracted from the reading for each P450 variant to
control for clarified lysate background. Additional
file 1 shows the standard curves for all P450 vari-
ants. Ten P450 variants had standard curve slopes
less than or equal to 0.020, indicating a low P450
concentration. These were the ten P450 variants
that we discarded from further analysis, since the
low P450 concentration decreased the accuracy of
the measurements.
To determine the activity on 12-pNCA, we mon-
itored the formation of the yellow 4-nitrophenolate
compound that is released upon hydroxylation of
the twelfth carbon in the 12-pNCA molecule [27,49].
Immediately before use, we prepared a 6× stock so-
lution of 12-pNCA by adding 3.6 parts of 4.17 mM
12-pNCA in DMSO to 6.4 parts 100 mM EPPS, pH
8.2. A multichannel pipette was used to add 20 µl
of this stock solution to each well of the microtiter
plates (which contained 80 µl of a dilution of clar-
ified lysate). The plates were briefly mixed, and
the absorbance was read at 398 nm. To initiate the
reactions, we then prepared a 6× stock solution of
24 mM hydrogen peroxide in 100 mM EPPS, pH
8.2, and immediately added 20 µl of this solution
to each well of the microtiter plate and mixed. The
final assay conditions were therefore 6% DMSO, 250
µM 12-pNCA, and 4 mM hydrogen peroxide. The
reactions were incubated on the benchtop for two
hours, and the total amount of enzymatic product
was quantified by the gain in absorbance at 398 nm.
At each dilution along the standard curve, the corre-
sponding null control lysate dilution was subtracted
from the reading to control for lysate background.
Additional file 1 shows the standard curves for all
P450 variants.
The activities on 2-phenoxyethanol, propra-
nolol, 11-phenoxyundecanoic acid, 2-amino-5-
chlorobenzoxazole, and 1,2-methylenedioxybenzene
were determined using the 4-aminoantipyrene (4-
AAP) assay [50, 51], which detects the formation
of phenolic compounds. For each of these five sub-
strates, immediately before use we prepared a 6×
substrate stock solution. These stock solutions were
6% DMSO and 6% acetone in 100 mM EPPS, pH
8.2, with an amount of substrate added so that
the substrate concentrations in the stock solutions
were: 150 mM for 2-phenoxyethanol, 30 mM for pro-
pranolol, 5 mM for 11-phenoxyundecanoic acid, 12
mM for 2-amino-5-chlorobenzoxazole, and 120 mM
for 1,2-methylenedioxybenzene. The stock solutions
were prepared by first dissolving the substrate in
the DMSO and acetone, and then adding the EPPS
buffer. In some cases, the stock solution became
cloudy upon addition of the buffer, but there was
no immediate precipitation, so we could still pipette
the stock solution. A multichannel pipette was used
to add 20 µl of the appropriate substrate stock so-
lution to each well of the microtiter plates (which
contained 80 µl of a dilution of clarified lysate). To
initiate the reactions, we then added 20 µl of the
freshly prepared 6× hydrogen peroxide stock solu-
tion (24 mM hydrogen peroxide in 100 mM EPPS,
pH 8.2) and mixed. We incubated the plates on the
benchtop for two hours. To detect the formation
of phenolic products, a pipetting robot was used to
add and mix 120 µl of quench buffer (4 M urea in
100 mM sodium hydroxide) to each well. We then
used the robot to add and mix 36 µl per well of
0.6% (w/v) of 4-aminoantipyrene in distilled wa-
ter, and immediately read the absorbance at 500
nm. To catalyze formation of the red compound
produced by coupling a phenolic compound to 4-
aminoantipyrene [50,51], we then used the pipetting
robot to add and mix 36 µl per well of 0.6% (w/v)
of potassium peroxodisulfate in distilled water. The
plates were incubated on the benchtop for 30 min-
utes, and the amount of product was quantified by
the gain in absorbance at 500 nm. At each dilu-
tion along the standard curve, the corresponding
null control lysate dilution was subtracted from the
reading to control for lysate background. Additional
file 1 show the standard curves for all P450 variants.
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In order to extract enzymatic activities from the
standard curves, we fit lines to the data points. For
some of the substrates (most notably 12-pNCA and
2-phenoxyethanol), many of the P450 variants were
sufficiently active to either saturate the substrate
or exceed the linear range of absorbance readings.
Therefore, we examined each standard curve by eye
to determine which points remained in the linear
range. Lines were then fit to the points in the linear
range. These fits are shown in Additional file 1. In
the plots in this file, all points that were deemed
to fall in the linear range (and so were used for the
fits) are shown as filled shapes, while all points that
were deemed to fall outside the linear range (and
so were not used in the fits) are shown as empty
shapes. The figures show the slopes of the lines for
all replicates (two replicates for all P450 variants
except for R1-11, which had four replicates). These
slopes are averaged for a best estimate of the slope,
and the standard error computed over these two
measurements is also reported.
To compare the activities (total substrate
turnovers per enzyme) among the different P450
variants, it is first necessary to normalize to the en-
zyme concentration. To do this, we took the ratio of
the slope for each substrate divided by the slope of
the CO different spectrum, propagating the errors.
These normalized slopes are proportional to the ac-
tivity on each substrate. The normalized slopes
are given in Additional file 2. This file also lists
the number of nonsynonymous mutations that each
P450 variant possesses relative to the R1-11 par-
ent sequence, as originally reported in [16]. These
normalized slopes allow for accurate comparisons
among the P450 variants, and were used in the
analyses in this paper. To convert these normalized
slopes into total substrate turnovers per enzyme, it
is necessary to multiply them by the ratio of extinc-
tion coefficients. The extinction coefficient for the
CO difference spectrum reading (the absorbance at
450 nm minus that at 490 nm) is 91 mM−1cm−1 [48],
and we calculated the extinction coefficient at 398
nm for the 4-nitrophenolate group in our buffer to be
12,000 M−1cm−1. Therefore, for 12-pNCA, the to-
tal number of substrate turnovers per P450 enzyme
is 7.58 times the ratio of the 12-pNCA standard
curve slope to the CO difference spectrum slope.
This indicates that our parent protein had about
250 12-pNCA turnovers per enzyme, compared to
the 1,000 reported for a variant engineered for maxi-
mal 12-pNCA activity [27]. For the other substrates
assayed with the 4-AAP assay, the extinction coeffi-
cient at 500 nm for the 4-AAP/phenol complex has
been reported to be 4,800 [51]. However, we believe
that this extinction coefficient could be of dubious
accuracy for our data. Depending on the exact type
of phenolic compound created by P450 hydroxyla-
tion, the extinction coefficient for the 4-AAP/phenol
complex may vary. Assuming the extinction coeffi-
cient of 4,800 M−1cm−1 is accurate, then the total
number of substrate turnovers per P450 enzyme is
19.0 times the ratio of the substrate standard curve
slope to the CO difference spectrum slope. Using
this coefficient, the parent P450 had roughly 1,000
turnovers on 2-phenoxyethanol, 30 turnovers on pro-
pranolol, 400 turnovers on 11-phenoxyundecanoic
acid, 50 turnovers on 2-amino-5-chlorobenzoxazole,
and 80 turnovers on 1,2-methylenedioxybenzene.
The high activities on 2-phenoxyethanol and 11-
phenoxyundecanoic acid are presumably due to the
fact that lack of polar substituents on the aromatic
ring allows these compounds to enter the hydropho-
bic P450 BM3 binding pocket [29] more easily than
12-pNCA. However, we emphasize that the exact
numerical values for the turnovers for these five sub-
strates are questionable. Definitive determination
of the extinction coefficients would require analyti-
cal analysis of the enzymatic products for each P450
variant on each substrate, which is beyond the scope
of this study.
Analysis of activity data
The raw activity values computed for the P450 vari-
ants are listed in Additional file 2. To analyze and
display this data, we computed the fold change in
activity of each variant relative to the R1-11 parent
P450. The fold change is simply the variant activity
divided by the parent activity on each substrate,
with the standard errors propagated to give an er-
ror on the fold change. In Figures 2 and 3, these
fold changes are displayed on a logarithmic scale so
that each unit corresponds to a two-fold increase
or decrease in activity. In Figure 2, the substrates
and the P450 variants have both been clustered, as
shown by dendrograms on the side of the heat map.
The clustering was performed using the standard
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hierarchical clustering function of the R statistical
package. This is complete linkage hierarchical clus-
tering, with the distances computed as the Euclidian
distance between the logarithms of the fold changes
in activity. The standard errors on the fold changes
in activity are not incorporated into Figure 2 or any
of the related analysis. However, these standard er-
rors are shown in Figure 3; it is apparent from this
figure that the errors tend to be much less than the
fold changes in activity themselves.
In Figure 4, the histogram bins are logarithmi-
cally spaced so that each bin contains a 20.5-fold
range of activities. For example, the histogram bin
centered at one contains all variants with between
2−0.25 = 0.84 and 20.25 = 1.19 fold the parental
activity, while the bin centered at 1.5 contains all
variants with between 20.25 = 1.19 and 20.75 = 1.68
fold the parental activity.
The principal component analysis shown in Ta-
ble 1 was performed using the R statistical package,
with inputs being the logarithms of the fold changes
in activity. Since these log fold changes in activity
contained no arbitrary units (they were already nor-
malized to the parent), the data was neither scaled
nor zeroed before performing the analysis. Table 1
shows the composition and the percent of variance
explained (the eigenvalue for that component di-
vided by the sum of all eigenvalues) for the first two
components. The remaining four components were
relatively unimportant, explaining 7%, 5%, 4%, and
2% of the total variance.
Phylogenetic tree
The phylogenetic tree shown in Figure 1 is based on
the number of nonsynonymous mutations the P450
variants have relative to the R-11 neutral evolution
parent, as reported in [16]. Each of the P450s that
evolved in a monomorphic population (prefix of M)
are known to have diverged independently, and so
are drawn on their own branch regardless of any se-
quence identity to other variants. The exact phylo-
genetic relationship of the P450s that evolved in the
polymorphic population (prefix of P) is not known,
so they portion of the tree for these mutants was
reconstructed by maximum parsimony. The tree is
based only on the nonsynonymous mutations, and
all mutations weighted equally. Full nucleotide and
amino acid sequences of the P450s can be found
in [16].
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Figure 1 - Phylogenetic tree of the neutrally evolved P450s
The tree shows the relationship among the 34 neutrally evolved P450 variants examined in this study. All
of the P450s neutrally evolved from the same R1-11 parent P450. The horizontal lengths of the branches
are proportional to the number of nonsynonymous mutations, as indicated by the scale bar. The vertical
arrangement of the branches is arbitrary.
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Figure 2 - Activities of the neutrally evolved P450s on the six substrates.
The heat map shows the fold change in activity of all 34 neutrally evolved P450 variant on all six substrates.
Each row shows the data for a different P450 variant, while each column shows the activity on a different
substrate. The fold change in activity is the ratio of the variant’s activity to that of the neutral evolution
parent. Both the substrates and the P450 variants are hierarchically clustered according to the activity
profiles, as shown by the dendrograms at top and left. Substrate abbreviations: PROP - propranolol, 2A5C
- 2-amino-5-chlorobenzoxazole, MDOB - 1,2-methylenedioxybenzene, 2PE - 2-phenoxyethanol, 11PA - 11-
phenoxyundecanoic acid. The standard errors for the changes in activity displayed in the heat map tend to
be much smaller than the changes themselves; these errors are shown explicitly in Figure 3.
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Figure 3 - Fold changes in P450 activities with standard errors.
The bar graphs show the fold change in activity of all 34 neutrally evolved P450 variants on all six substrates.
This is the same data as in Figure 2, except these graphs also give error bars showing the standard errors in
two separate measurements of the activities. In most cases the standard errors are much smaller than the
activity changes themselves.
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Figure 4 - Distributions of activity changes on each of the six substrates.
The histograms show the distributions of fold changes in activity for all 34 neutrally evolved P450 variants
on each of the six substrates, with a value of one indicating that the activity is the same as the neutral
evolution parent.
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Tables
Table 1 - Principal component analysis of activity profiles.
The first two principal components explain 82% of the variance in P450 activity profiles. The table shows
the composition of these two components and the variance explained by each. The first component contains
positive contributions from all substrates and can be thought of as representing a general high catalytic
ability. The second component can be thought of as representing discrimination between fused ring substrates
(PROP, 2A5C, and MDOB) and phenolic either substrates (12-pNCA, 11PA, 2PE). Substrate abbreviations
are as defined in the legend to Figure 2. The analysis was performed on the logarithms of the fold changes
in activity.
12-pNCA 2PE PROP 11PA 2A5C MDOB
PC1 (explains 62% of variance) 0.25 0.61 0.05 0.29 0.47 0.51
PC2 (explains 20% of variance) -0.48 -0.39 0.14 -0.27 0.70 0.19
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Table 2 - Correlations between changes in activity and number of mutations.
The extent of change in activity is positively correlated with the number of nonsynonymous mutations the
P450 has undergone relative to the neutral evolution parent. Each column shows the Pearson correlation
between the number of nonsynonymous mutations and the absolute value of the logarithm of the fold change
in activity for a different substrate, computed over all 34 P450 variants. The final column (ALL) is the
correlation among the 6×34 pooled data points for all six substrates. The P -values are shown in parentheses;
none of the correlations for the individual substrates are significant at a 1% level (due to the small number
of data points), but the overall correlation for all substrates is highly significant. Substrate abbreviations
are as defined in the legend to Figure 2.
12-pNCA 2PE PROP 11PA 2A5C MDOB ALL
Correlation 0.32 (0.06) 0.27 (0.11) 0.06 (0.71) 0.12 (0.48) 0.20 (0.24) 0.36 (0.04) 0.22(10−3)
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Additional Files
Additional file 1 — Standard curves used to determine P450 activities.
The PDF file shows all of the standard curves used to determine the P450 concentration and enzymatic
activities. Points that were deemed to fall in the linear range, and so used to compute the standard curve
slopes, are solid. Points that were deemed outside of the linear range are empty. Each curve shows the
slopes computed for two independent replicates, and the average slope with standard error. These average
slopes were used to compute the P450 activities.
Additional file 2 — Raw activity and sequence data.
The text file gives the activities of the P450 variants on each of the six substrates, as measured in this study.
It also lists the number of nonsynonymous mutations (M NS) relative to the R1-11 neutral evolution parent
sequence, as originally reported in [16]. Each row lists the data for a different P450 variant, and standard
errors for the measured activities are shown in parentheses. Activities are the normalized standard curve
slopes as described in the Methods.
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